Janssen Biotech, Inc.

Centocor Ortho Biotech Inc.

Hanssen Biotech, Inc

Steven Jacobs

Karyn O'Neil

Michael Diem

Rebecca Hawkins

Manuel Sepulveda

Linus Hyun

Donna Klein

Shalom Goldberg

Ricardo Attar

Sheri Moores

Kristen Picha

Alastair King

Mark L Anderson

Tracy Spinka-Doms

Rosa Cardoso

Tricia Lin

Karyn O'neil

Jinquan Luo

Michael Baumann

Sanjaya Singh

Sheng-Jiun Wu

Alexey Teplyakov

Rajkumar Ganesan

Francois Gaudet

Adam Zwolak

Yiqing Feng

Thomas Rutkoski

Colleen Kane

Yingzhe Li

Glenn Mark Anderson

Jill Marie Mooney

Fang Yi

Sherry La Porte

Raymond Brittingham

Ronan McDaid

Benjamin J Harman

Jennifer Nemeth-Seay

Triveni K Bhatt

Michael Dennis Feldkamp

Scott R Brodeur

Gaby Tresch

Gaby Sennhauser

Steven Pomerantz

Galla Chandra Rao

Jaclyn Hoover

Leopoldo Luistro

Anderson Mark

Mark Anderson

Karen O'NEIL

Deirdra Bethea

The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Proteins comprising CD3 antigen binding domains and uses thereof

Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

EGFR and C-met fibronectin type III domain binding molecules

A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

Fibronectin type III domain based scaffold compositions, methods and uses

FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

CD137 binding fibronectin type III domains

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Prostate specific membrane antigen binding fibronectin type iii domains

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

CD8A-binding fibronectin type III domains

Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Serum albumin-binding fibronectin type III domains

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered fibronectin type III domain binding molecules

FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

PD-L1 binding fibronectin type III domains

EGFR and c-Met fibronectin type III domain binding molecules

Growing community of inventors

Spring House, PA, United States of America

Steven Jacobs